CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line treatment (EOT), as defined by positive measurable residual disease detected by Foresight CLARITY (PhasED-seq). Participants will initially be pre-screened for MRD status after first line treatment (1L) with chemoimmunotherapy including a CD20 monoclonal antibody and anthracycline.

Trial Details

NCT ID

NCT07443137

Phase

PHASE1

Sponsor

Stanford University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Rapcabtagene autoleucel (YTB323)

Locations (sample)

Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

Eligibility for Pre-Screening:
Diagnosis: Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2022\[1\]:
Diffuse large B cell lymphoma (DLBCL); OR
Primary mediastinal (thymic) large B cell lymphoma; OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →